Who Is Getting HRT on the NHS?

Blog · Women's Health

Who Is Getting HRT on the NHS?

By Vitae Team ·

NHS HRT prescribing in England has risen almost fivefold in a decade. What the new figures count, what they exclude, and why they cannot measure unmet need.

NHS HRT prescribing in England has risen almost fivefold in a decade, to more than three million identified patients in 2025/26. The latest figures also show large differences by deprivation and by where people live. What they cannot show is whether treatment is reaching the women who need it, and the NHS body that publishes them says so in the release itself.

TL;DR

  • Items rose from 3,518,127 in 2016/17 to 16,525,240 in 2025/26. Identified patients went from 1,138,221 to 3,059,192.
  • Items grew faster than patients last year, 12% against 9.1%. That raised the average number of items per patient, though the figures cannot explain why.
  • The count is of patients, not of women. It covers everyone prescribed a drug on the HRT prepayment certificate list, and the age bands include children and people in their nineties.
  • 829,000 patients in the least deprived fifth of England against 372,000 in the most deprived. Those are patient counts, not population-adjusted rates.
  • Geography varies widely. An estimated 23 patients per 1,000 residents in North East London against 77 in Cornwall and the Isles of Scilly, with an England average of 52.
  • No clinical reason is recorded for any prescription, and private prescriptions, hospital and prison prescribing are all excluded.
  • NHSBSA states that unmet demand for treatment is not in the data. That is the limit on every comparison in the release.

01 What has risen, and what it counts

The NHS Business Services Authority published its latest HRT figures on 12 November. Items in England rose from 3,518,127 in 2016/17 to 16,525,240 in 2025/26. Identified patients went from 1,138,221 to 3,059,192. Year on year, items were up 12% and patients up 9.1%. The largest age band is 50 to 54, at 664,000 patients, followed by 55 to 59 at 603,000.

Items and patients measure different things, and the gap between those growth rates is worth noting rather than explaining. Items rising faster than patients means the average number of items per identified patient went up, to roughly five and a half across the year. The published totals cannot say whether that came from longer treatment, more products per person, shorter dispensing intervals or a change in who is being treated.

The mix also moved. Micronised progesterone 100mg capsules were the most prescribed presentation at 2.0 million items, up 57% in a year. Two of the next three are local vaginal preparations rather than systemic HRT, which is a reminder that the headline number bundles several different kinds of prescribing. An HRT prepayment certificate, £19.80 and introduced in April 2023, was used for 23% of items, up from 21%.

One thing the release makes plain and most coverage does not. These are patients, not women. The publication counts everyone dispensed a drug on the prepayment certificate list, and it contrasts itself with a separate NHSBSA report restricted to female patients aged 40 and over. The age breakdown runs from under five to over ninety. The overwhelming majority are women in midlife, but this is a count of a drug list, not a count of women receiving menopausal HRT, and some drugs on the list are not HRT when prescribed alone.

02 Where the differences show up

On deprivation the publication reports patient counts rather than rates. In 2025/26 there were 829,000 identified patients in the least deprived fifth of England and 372,000 in the most deprived, with the three middle quintiles rising steadily in between. NHSBSA describes the pattern as consistent since 2015/16. It is a wide and long-standing gradient, but it is a comparison of how many patients appear, not of how many appear per head of population.

The rates it does publish are geographical, and they are per 1,000 residents of all ages and both sexes rather than per 1,000 women. North East London had the lowest at an estimated 23 per 1,000, Cornwall and the Isles of Scilly the highest at 77, against an England average of 52. NHSBSA cautions that even this comparison is imperfect, because the local figures use mid-2024 population estimates and the national average mid-2025. Sukhi Basra, vice chair of the National Pharmacy Association, called the variation an unfair postcode lottery affecting women in deprived communities. Sue Mann, national clinical director for women's health at NHS England, said it was important that women currently least well served are not forgotten.

Ethnicity is not in this release at all. The figures usually quoted alongside it come from the Menopause All-Party Parliamentary Group's Health of the Nation report, published in October 2025, which used an ECLIPSE analysis of 1.85 million women aged 45 to 55 drawn from 28 million patient records. It reported 23.3% of white women on HRT, against 6.2% of Asian women and 5.2% of Black women, and 23% in the most affluent group against 12% in the most deprived. That is a different dataset, a different population and a year older. It is worth having as context, and it is not part of this week's figures.

03 What the figures cannot settle

The release is unusually direct about its own limits. It covers only drugs on the HRT prepayment certificate list, prescribed in England and dispensed in the community. Prescriptions issued and dispensed in hospitals and prisons are excluded, as are private prescriptions. How much menopause care in England happens privately is not quantified here, so the effect of that exclusion on any particular area is unknown.

More fundamentally, NHSBSA states that it does not capture the clinical indication of a prescription and therefore does not know the reason why a prescription was issued, or the condition it is intended to treat. It goes further in the limitations, saying the statistics do not include prescriptions issued but not presented for dispensing, or where there has been an unmet demand for treatment. A British Menopause Society spokesperson made the same point about the coverage, saying the data do not show why prescribing has risen, nor whether it now matches clinical need.

There is also a comparability problem that cuts against the obvious trend story. This release uses the English indices of deprivation 2025 where earlier ones used the 2019 version, has moved to the 2026 integrated care board structure, and has had further drug presentations added to the certificate list. NHSBSA warns that historical figures can change when methodology changes between releases. It also states plainly that these figures are not directly comparable with its separate inequalities report, which uses a different medicine list and covers only women aged 40 and over.

What This Actually Means

The NHS can count how much HRT it dispenses with considerable precision, down to the individual item and the individual presentation. It cannot count the appointment that did not happen, the symptom not raised, or the request that went nowhere. Those are the two things a reader would most want to know, and the release says outright that the second is outside its scope.

That is why the obvious reading of the deprivation figures needs care. A lower count in a deprived area is consistent with people not being offered treatment, with shorter appointments and less continuity of care. It is also consistent with differences in symptom reporting, in what people want, in population age structure, and in how much of the care in an area is happening privately. The gradient is clear and it has been there for a decade. Its cause is not established by these numbers, and the release does not claim it is.

Nor would equal prescribing rates across every group prove the system was working, any more than the fivefold rise proves it already is. More prescribing is not automatically better care, and a figure that counts a drug list rather than a condition cannot be read as a measure of menopause care at all. What a reader can take from this is narrower and more useful. There is a large and persistent difference in who ends up on NHS HRT, it tracks deprivation and geography, and this dataset cannot tell anyone whether access matches need.

Frequently Asked Questions

How much has HRT prescribing risen?

Items in England went from 3,518,127 in 2016/17 to 16,525,240 in 2025/26, and identified patients from 1,138,221 to 3,059,192. That is close to fivefold on items and slightly under threefold on patients.

Why do items and patients grow at different rates?

Because one counts dispensing events and the other counts people. When items rise faster, the average number of items per patient goes up, which the published totals record without explaining.

Are these three million women?

Not exactly. The publication counts all patients prescribed a drug on the HRT prepayment certificate list, and its age bands run from under five upwards. Most will be women in midlife, but it is a drug-list count rather than a count of women on menopausal HRT.

Does a lower figure in deprived areas mean people are being denied treatment?

The data cannot say. It records no clinical reason for any prescription and excludes private prescribing, so the difference is clearly there while its cause is not established by these figures.

Where do the figures on ethnicity come from?

Not from this release. They come from the Menopause APPG's Health of the Nation report of October 2025, using a separate analysis of 1.85 million women aged 45 to 55.

The Bottom Line

NHS HRT prescribing in England has risen almost fivefold in a decade, to 16.53 million items and 3.06 million identified patients in 2025/26. Within that, the least deprived fifth of the country accounts for 829,000 patients against 372,000 in the most deprived, a gradient NHSBSA says has been consistent since 2015/16, and the spread between local health systems runs from 23 patients per 1,000 residents to 77.

What the figures cannot do is tell anyone whether treatment is reaching the people who need it. They record dispensing, not need and not refusal, and the publication states that unmet demand for treatment is not in the data. England now has a detailed picture of how much HRT it hands out. These statistics are not the thing that would tell us whether menopause care is working. Our Perimenopause Reset sets out what the diagnosis rests on, and we have covered the UK approval of testosterone cream for women separately.

This article is for general information and is not medical advice. If you have symptoms or concerns, speak to your GP.

Sources

  • NHS Business Services Authority. Hormone Replacement Therapy, England, April 2016 to June 2026. Published 12 November 2026. https://nhsbsa-opendata.s3.eu-west-2.amazonaws.com/hrt/hrt_June_2026_v001.html
  • NHS Business Services Authority. Hormone Replacement Therapy, England, background and methodology, November 2026. https://nhsbsa-opendata.s3.eu-west-2.amazonaws.com/hrt/hrt_background_nov26_v001.html
  • NHS Business Services Authority. Hormone Replacement Therapy, England, April 2016 to June 2026 collection page. https://www.nhsbsa.nhs.uk/statistical-collections/hormone-replacement-therapy-england/hormone-replacement-therapy-england-april-2016-june-2026
  • HRT prescriptions five times higher than ten years ago. The Pharmaceutical Journal, 16 November 2026. https://pharmaceutical-journal.com/article/news/hrt-prescriptions-five-times-higher-than-ten-years-ago
  • HRT prescribing rose 12% last year but inequalities persist. The Pharmacist, 13 November 2026. https://www.thepharmacist.co.uk/clinical/womens-health-clinical/hrt-prescribing-rose-12-last-year-but-inequalities-persist/
  • Menopause All-Party Parliamentary Group. Health of the Nation Report in Relation to Hormone Replacement Therapy, October 2025. (ECLIPSE analysis; reported by Wellbeing of Women.) https://www.wellbeingofwomen.org.uk/news/new-data-reveals-big-gap-in-access-to-hormone-replacement-therapy-for-ethnic-minority-and-deprived-women/